Comparative effectiveness of bovine carotid artery xenograft and polytetrafluoroethylene in hemodialysis access revision

Author:

Heindel Patrick12ORCID,Feliz Jessica D12,Fitzgibbon James J12,Rouanet Eva12,Belkin Michael1,Hentschel Dirk M3ORCID,Ozaki C Keith1,Hussain Mohamad A12ORCID

Affiliation:

1. Department of Surgery, Division of Vascular and Endovascular Surgery, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA

2. Center for Surgery and Public Health, Department of Surgery, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA

3. Department of Medicine, Division of Renal Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, USA

Abstract

Background: When hemodialysis arteriovenous accesses fail, autogenous options are often limited. Non-autogenous conduit choices include bovine carotid artery xenografts (BCAG) and expanded polytetrafluoroethylene (PTFE), yet their comparative effectiveness in hemodialysis access revision remains largely unknown. Methods: A cohort study was performed from a prospectively collected institutional database from August 2010 to July 2021. All patients undergoing an arteriovenous access revision with either BCAG or PTFE were followed for up to 3 years from their index access revision. Revision was defined as graft placement to address a specific problem of an existing arteriovenous access while maintaining one or more of the key components of the original access (e.g. inflow, outflow, and cannulation zone). Outcomes were measured starting at the date of the index revision procedure. The primary outcome was loss of secondary patency at 3 years. Secondary outcomes included loss of post-intervention primary patency, rates of recurrent interventions, and 30-day complications. Pooled logistic regression was used to estimate inverse probability weighted marginal structural models for the time-to-event outcomes of interest. Results: A total of 159 patients were included in the study, and 58% received access revision with BCAG. Common indications for revision included worn out cannulation zones (32%), thrombosis (18%), outflow augmentation (16%), and inflow augmentation (13%). Estimated risk of secondary patency loss at 3 years was lower in the BCAG group (8.6%, 3.9–15.1) compared to the PTFE group (24.8%, 12.4–38.7). Patients receiving BCAG experienced a 60% decreased relative risk of secondary patency loss at 3 years (risk ratio 0.40, 0.14–0.86). Recurrent interventions occurred at similar rates in the BCAG and PTFE groups, with 1.86 (1.31–2.43) and 1.60 (1.07–2.14) interventions at 1 year, respectively (hazard ratio 1.22, 0.74–1.96). Conclusions: Under the conditions of this contemporary cohort study, use of BCAG in upper extremity hemodialysis access revision decreased access abandonment when compared to PTFE.

Funder

brigham and women’s hospital

national heart, lung, and blood institute

Publisher

SAGE Publications

Subject

Nephrology,Surgery

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3